Syngene stock price dropped after management issued cautious outlook during quarterly results. The company has reduced FY24 guidance due to slowdown in the US biotech segment.
Ace investor Rakesh Jhunjhunwala has raised his stake in Lupin during the last quarter. Pharmaceutical sector has witnessed strong performance after COVID-19 pandemic led to lockdowns.